Urinary Proteomics Enables Noninvasive and Longitudinal Monitoring of Tumor Burden Dynamics and Early Recurrence in Hepatocellular Carcinoma
Molecular & Cellular Proteomics · 2026
DOI: 10.1016/j.mcpro.2026.101635 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026. Verfasst von Xiaohua Xing und 10 weiteren Autor:innen. Beteiligte Einrichtung: The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical Unive…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Recurrence, Local, Proteomics. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fuzhou Municipal Health Commission, China Postdoctoral Science Foundation, International Science and Technology Cooperation Programme.
Abstract (Originalsprache)
To develop a noninvasive, urine-based approach for dynamic monitoring of tumor burden and early detection of recurrence in hepatocellular carcinoma (HCC), addressing the limited sensitivity of conventional serum biomarkers such as AFP and DCP, particularly for minimal residual disease (MRD) assessment. We established a prospective, multi-cohort urinary proteomics framework encompassing four longitudinal clinical cohorts (378 patients, 972 urine samples). In the discovery cohort, 26 patients contributed 130 longitudinal urine samples from those undergoing primary and secondary resections, which were analyzed by mass spectrometry at five standardized follow-up time points to identify proteins associated with tumor burden dynamics. The validation cohort (n = 46) used parallel reaction monitoring (PRM) to confirm candidate biomarkers and construct a composite urine-based tumor burden monitoring model integrating HPGD, AFP, DCP, and GGT. The model was then applied to an early recurrence cohort (306 patients, 612 urine samples) to detect MRD and predict recurrence prior to radiological confirmation. Among 8563 quantified urinary proteins, 217 significantly correlated with tumor burden, with HPGD closely mirroring dynamic changes. The integrated model achieved a pre-recurrence AUC of 0.86, sensitivity of 73%, and specificity of 87%, outperforming AFP (0.73, 39%, 96%) and DCP (0.64, 59%, 88%). It predicted recurrence a median 4.1 months earlier than imaging and served as an independent prognostic factor for recurrence-free (RFS) and overall survival (OS, p < 0.001). This urine-based model enables dynamic assessment of tumor burden and early recurrence detection, surpassing conventional serum biomarkers and providing a clinically actionable tool for personalized surveillance and therapeutic decision-making in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China; Department of Pathology, Institute of Oncology,…
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
- Department of Proteomics, Tianjin Key Laboratory of Clinical Multi-Omics, Tianjin, China.
- The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China. Electronic address: yingchaowang@live.com.
Förderung
- Fuzhou Municipal Health Commission
- China Postdoctoral Science Foundation
- International Science and Technology Cooperation Programme
- National Natural Science Foundation of China
- Joint Fund of the National Natural Science Foundation of China and the Karst Science Research Center of Guizhou Province
Zitieren
APA
Xing, X., Hu, E., Song, L., Zheng, Z., Cai, L., Ouyang, J., Li, J., Pan, X., Liu, M., Wang, Y., & Liu, X. (2026). Urinary Proteomics Enables Noninvasive and Longitudinal Monitoring of Tumor Burden Dynamics and Early Recurrence in Hepatocellular Carcinoma. Molecular & Cellular Proteomics. https://doi.org/10.1016/j.mcpro.2026.101635
Vancouver
Xing X, Hu E, Song L, Zheng Z, Cai L, Ouyang J, et al. Urinary Proteomics Enables Noninvasive and Longitudinal Monitoring of Tumor Burden Dynamics and Early Recurrence in Hepatocellular Carcinoma. Molecular & Cellular Proteomics. 2026. doi:10.1016/j.mcpro.2026.101635
BibTeX
@article{Xing2026,
author = {Xing, Xiaohua and Hu, En and Song, Lei and Zheng, Zhao and Cai, Linsheng and Ouyang, Jiahe and Li, Jie and Pan, Xinting and Liu, Mingxin and Wang, Yingchao and Liu, Xiaolong},
title = {Urinary Proteomics Enables Noninvasive and Longitudinal Monitoring of Tumor Burden Dynamics and Early Recurrence in Hepatocellular Carcinoma},
journal = {Molecular & Cellular Proteomics},
year = {2026},
doi = {10.1016/j.mcpro.2026.101635}
}
EUVIMED